Adrian Jubb
Affiliations: | 2007-2011 | University of Oxford, Oxford, United Kingdom |
Google:
"Adrian Jubb"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Milani M, Venturini S, Bonardi S, et al. (2017) Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. Oncotarget. 8: 78870-78881 |
| Oon CE, Bridges E, Sheldon H, et al. (2017) Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth. Oncotarget |
| Mehta S, Hughes NP, Li S, et al. (2016) Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. Ebiomedicine |
| Chen TT, Filvaroff E, Peng J, et al. (2015) MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation. Ebiomedicine. 2: 406-20 |
| Ong CC, Gierke S, Pitt C, et al. (2015) Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Research : Bcr. 17: 59 |
| Zhou W, Jubb AM, Lyle K, et al. (2014) PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. The Journal of Pathology. 234: 502-13 |
| Oon CE, Bridges E, Sheldon H, et al. (2014) Functional comparison of Notch ligands in tumour angiogenesis Asian Pacific Journal of Tropical Disease. 4: 229 |
| Blick C, Ramachandran A, Wigfield S, et al. (2013) Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer. British Journal of Cancer. 109: 50-9 |
| Brauer MJ, Zhuang G, Schmidt M, et al. (2013) Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3681-92 |
| Ong CC, Jubb AM, Jakubiak D, et al. (2013) P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. Journal of the National Cancer Institute. 105: 606-7 |